Atlas Trials

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Clinical trial NCT04427787 · UNKNOWN

Trial details

NCT number
NCT04427787
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors
Start date
2020-06-20
Primary completion
2023-11-01
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.